Free Trial
NYSE:MTNB

Matinas Biopharma 5/10/2023 Earnings Report

Matinas Biopharma logo
$1.03 0.00 (0.00%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.01 -0.02 (-1.46%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas Biopharma EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.03
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Matinas Biopharma Revenue Results

Actual Revenue
$1.10 million
Expected Revenue
$0.30 million
Beat/Miss
Beat by +$800.00 thousand
YoY Revenue Growth
N/A

Matinas Biopharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Matinas Biopharma Earnings Headlines

MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha
Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance
Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
Matinas BioPharma files to sell 16.9M shares of common stock for holders
See More Matinas Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email.

About Matinas Biopharma

Matinas Biopharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company specializing in the development of novel lipid-based drug products that enhance the delivery and efficacy of existing therapies. Leveraging its proprietary Lipid NanoCrystal (LNC) platform, Matinas focuses on improving the bioavailability and targeted delivery of pharmaceutical compounds, particularly in the areas of anti-infectives and cardiovascular disease. The company’s mission is to address unmet medical needs by transforming how drugs are formulated and administered.

The company’s lead product candidate, MAT2203 (formerly iCo-010), is an oral formulation of amphotericin B designed to treat life-threatening fungal infections such as cryptococcal meningitis. Preclinical and early clinical data suggest that MAT2203 may offer improved tolerability and reduced toxicity compared to current intravenous formulations, potentially enabling outpatient treatment. In addition to its antifungal franchise, Matinas is advancing lipid-based formulations of omega-3 fatty acids for cardiovascular health, seeking to optimize absorption and dosing convenience.

Founded in 2014 and headquartered in Bedminster, New Jersey, Matinas Biopharma operates research and development facilities in the United States and collaborates with academic institutions and contract research organizations worldwide. The company holds a portfolio of patent families covering its LNC platform and specific drug candidates, and it continues to explore partnerships that can accelerate clinical development and regulatory approval across multiple therapeutic areas.

Matinas Biopharma’s leadership team combines expertise in pharmaceutical development, regulatory affairs, and commercial strategy. Chief Executive Officer John H. Johnson, Ph.D., brings more than two decades of experience in drug discovery and product development, while Chief Financial Officer Tracey Franklin oversees corporate finance and investor relations. The company’s governance structure includes a board of directors with seasoned industry veterans who guide Matinas through its clinical trials and toward potential commercialization.

View Matinas Biopharma Profile

More Earnings Resources from MarketBeat